An inducible, ligand-independent receptor activator of NF-κB gene to control osteoclast differentiation from monocytic precursors

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Rementer, Cameron W ^a   Wu, Meiting ^a   Buranaphatthana, Worakanya ^b   Yang, Hsueh Ying L ^a   Scatena, Marta ^a   Giachelli, Cecilia M ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, MOUSE;

ANIMAL; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; GENETICS; METABOLISM; MYELOID PROGENITOR CELL; OSTEOCLAST;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; MYELOID PROGENITOR CELLS; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND;

EID: 84893599507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084465     Document Type: Article

References (39)

1. Giachelli CM (1999) Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol 154: 671-675.
2. Forsberg JA, Potter BK (2010) Heterotopic ossification in wartime wounds. J Surg Orthop Adv 19: 54-61.
3. Roberts JB, Pankratz DG (1979) The surgical treatment of heterotopic ossification at the elbow following long-term coma. J Bone Joint Surg Am 61: 760-763. (Pubitemid 9232035)
4. Shehab D, Elgazzar AH, Collier BD (2002) Heterotopic ossification. J Nucl Med 43: 346-353. (Pubitemid 34208096)
5. Hashem R, Tanzer M, Rene N, Evans M, Souhami L (2011) Postoperative radiation therapy after hip replacement in high-risk patients for development of heterotopic bone formation. Cancer Radiother 15: 261-264.
6. Mohler ER, Gannon F, Reynolds C, Zimmerman R, Keane MG, et al. (2001) Bone formation and inflammation in cardiac valves. Circulation 103: 1522-1528. (Pubitemid 32226259)
7. Simpson CL, Lindley S, Eisenberg C, Basalyga DM, Starcher BC, et al. (2007) Toward cell therapy for vascular calcification: osteoclast-mediated demineralization of calcified elastin. Cardiovasc Pathol 16: 29-37. (Pubitemid 46049030)
8. Lippuner K (2012) The future of osteoporosis treatment - a research update. Swiss Med Wkly 142: w13624.
9. Ollivere B, Wimhurst JA, Clark IM, Donell ST (2012) Current concepts in osteolysis. J Bone Joint Surg Br 94: 10-15.
10. nd Edition 187-202.
11. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, et al. (1999) The TNFR related protein RANK is the osteoclast differentiation and activation receptor for osteoprotegerin ligand. Proc Natl Acad Sci 96: 3540-3545. (Pubitemid 29168945)
12. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R (2004) Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2: 6.
13. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179. (Pubitemid 27507987)
14. Lee ZH, Kim HH (2003) Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305: 211-214. (Pubitemid 36555454)
15. Wada T, McKee MD, Steitz S, Giachelli CM (1999) Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 84: 166-178. (Pubitemid 29070112)
16. Liu C, Walter TS, Huang P, Zhang S, Zhu X, et al. (2010) Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol 184: 6910-6919.
17. Blau CA, Peterson KR, Drachman JG, Spencer DM (1997) A proliferation switch for genetically modified cells. Proc Natl Acad Sci U S A 94: 3076-3081. (Pubitemid 27157266)
18. Jin L, Asano H, Blau CA (1998) Stimulating cell proliferation through the pharmacologic activation of c-kit. Blood 91: 890-897. (Pubitemid 28078291)
19. Weinreich MA, Lintmaer I, Wang L, Liggitt HD, Harkey MA, et al. (2006) Growth factor receptors as regulators of hematopoiesis. Blood 108: 3713-3721. (Pubitemid 44864549)
20. Zeng H, Masuko M, Jin L, Neff T, Otto KG, et al. (2001) Receptor specificity in the self-renewal and differentiation of primary multipotential hemopoietic cells. Blood 98: 328-334.
21. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK (2007) Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13: 913-924. (Pubitemid 47055386)
22. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR (1993) Controlling signal transduction with synthetic ligands. Science 262: 1019-1024. (Pubitemid 24035037)
23. Neff T, Blau CA (2001) Pharmacologically regulated cell therapy. Blood 97: 2535-2540.
24. Whitney ML, Otto KG, Blau CA, Reinecke H, Murry CE (2001) Control of myoblast proliferation with a synthetic ligand. J Biol Chem 276: 41191-41196.
25. Dismuke AD, Kohn AD, Moon RT, Wong MH (2009) Lentiviral-mediated transgene expression can potentiate intestinal mesenchymal-epithelial signaling. Biol Proced Online 11: 130-144.
26. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471. (Pubitemid 28471781)
27. Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1: 241-245.
28. Courter DL, Lomas L, Scatena M, Giachelli CM. (2005) Src Kinase Activity Is Required for Integrin αVβ3-Mediated Activation of Nuclear Factor-κB. J Biol Chem 280:12145-12151.
29. Janckila AJ, Takahashi K, Sun SZ, Yam LT (2001) Naphthol-ASBI phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b. J Bone Miner Res 16: 788-793. (Pubitemid 32230609)
30. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, et al. (1998) NFkappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 141: 1083-1093. (Pubitemid 28243974)
31. Boyde A, Ali NN, Jones SJ (1984) Resorption of dentine by isolated osteoclasts in vitro. Br Dent J 156: 216-220.
32. Osathanon T, Linnes ML, Rajachar RM, Ratner BD, Somerman MJ, et al. (2008) Microporous nanofibrous fibrin-based scaffolds for bone tissue engineering. Biomaterials 29: 4091-4099.
33. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342. (Pubitemid 40852708)
34. Blair HC, Robinson LJ, Zaidi M (2005) Osteoclast signalling pathways. Biochem Biophys Res Commun 328: 728-738. (Pubitemid 40208310)
35. Iwamoto K, Miyamoto T, Sawatani Y, Hosogane N, Hamaguchi I, et al. (2004) Dimer formation of receptor activator of nuclear factor kappaB induces incomplete osteoclast formation. Biochem Biophys Res Commun 325: 229-234. (Pubitemid 39441183)
36. Pohjolainen V, Taskinen P, Soini Y, Rysä J, Ilves M, et al. (2008) Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Hum Pathol 39: 1695-1701.
37. Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB (2011) RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 19: 2035-2040.
38. Pichardo SE, Kuypers SC, van Merkesteyn JP (2012) Denosumab osteonecrosis of the mandible: A new entity? A case report. J Craniomaxillofac Surg 41: e65-e69.
39. Paparodis R, Buehring B, Pelley E, Binkley N (2013) A Case of an Unusual Subtrochanteric Fracture in a Patient Receiving Denosumab. Endocr Pract: 1-17.